Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys $301,971.96 in Stock

Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L purchased 27,502 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $10.98 per share, for a total transaction of $301,971.96. Following the acquisition, the director now owns 7,981,725 shares in the company, valued at $87,639,340.50. This trade represents a 0.35 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Suvretta Capital Management, L also recently made the following trade(s):

• On Tuesday, December 3rd, Suvretta Capital Management, L purchased 42,000 shares of Benitec Biopharma stock. The shares were acquired at an average price of $9.60 per share, with a total value of $403,200.00.

Benitec Biopharma Price Performance

BNTC traded up $0.42 during trading on Thursday, reaching $12.00. The company had a trading volume of 30,035 shares, compared to its average volume of 48,807. The company has a market cap of $278.59 million, a P/E ratio of -4.23 and a beta of 0.89. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $13.29. The business’s fifty day moving average price is $10.88 and its 200 day moving average price is $9.52.

Institutional Trading of Benitec Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of BNTC. GAMMA Investing LLC boosted its stake in shares of Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,102 shares during the period. Geode Capital Management LLC raised its position in shares of Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after buying an additional 20,012 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in Benitec Biopharma during the third quarter worth $274,000. Simplify Asset Management Inc. bought a new position in Benitec Biopharma in the second quarter valued at about $358,000. Finally, Nantahala Capital Management LLC acquired a new stake in Benitec Biopharma in the second quarter valued at approximately $5,881,000. Institutional investors own 52.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BNTC. Piper Sandler reaffirmed an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Baird R W raised Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird started coverage on Benitec Biopharma in a research report on Friday, December 13th. They issued an “outperform” rating and a $30.00 target price on the stock. HC Wainwright assumed coverage on shares of Benitec Biopharma in a report on Monday, December 16th. They set a “buy” rating and a $28.00 target price on the stock. Finally, JMP Securities raised their price target on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research note on Monday, October 14th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Benitec Biopharma currently has a consensus rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.